As of Friday, January 30, Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 16.32%, which has investors ...

THE WOODLANDS, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company has made the strategic decision to eliminate its commercial ...

SONATA-HCM on track for enrollment completion in 2026 and topline data in 2027 $10 million milestone payment triggered from licensing agreement with Novo Nordisk for LX9851 Zynquista on track for NDA ...

Investing.com -- Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) stock fell 14.9% Friday after the company announced the pricing of ...

During the last three months, 6 analysts shared their evaluations of Lexicon Pharmaceuticals (NASDAQ:LXRX), revealing diverse outlooks from bullish to bearish. The following table summarizes their ...

Jefferies and Piper Sandler are acting as joint book-running managers for the proposed offering.

Lexicon Pharmaceuticals' launch of Inpefa continues to progress very slowly; prescriptions grew nearly 50% QoQ, but revenue is still below $2M and missing sell-side expectations. New leadership and ...

Lexicon Pharmaceuticals won't take no for an answer. The Texas pharma—convinced of the value of its diabetes candidate sotagliflozin—has clapped back at its latest rejection from the FDA, asking to be ...

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is one of the best fast growing penny stocks to buy according to analysts. On ...